GENESIS Pharma
GENESIS Pharma is a biopharmaceutical company specializing in the commercialization of innovative pharmaceutical products for serious and rare diseases in Central and Eastern Europe. Established in 1997, GENESIS Pharma was the first pharmaceutical company in Greece and one of the first in Europe to focus on the sales, marketing and distribution of biopharmaceutical products. Shortly after its founding, the company began to steadily expand at a regional level, today covering most countries in the CEE region.
The robust network of its strategic partnerships comprises leading international pharmaceutical companies dedicated to cutting-edge R&D, alongside fast-growing biopharmaceutical companies with pioneering research and disruptive innovations in the development of targeted, specialized treatments for orphan diseases.
In total, GENESIS Pharma holds a product portfolio covering over 30 serious and rare diseases, predominantly within the therapeutic areas of neurology, genetic diseases, oncology, hematology, rheumatology, dermatology, nephrology, gastroenterology, and cardiology.
In Greece, the company is the largest among Greek companies specializing in innovative medicines, based on turnover, as well as one of the most awarded companies for its commitment to sustainable development and good working environment.
INTERNATIONAL PARTNERS
Biogen International GMBH, PharmaMar S.A., Incyte Biosciences International Sarl, Amicus Therapeutics Europe Limited, Alnylam Netherlands B.V., Vifor Fresenius Medical Care Renal Pharma Ltd, Vifor International AG, JAZZ Pharmaceuticals Ireland Limited, Pfizer (Substitution Seagen B.V), Kyowa Kirin, Regeneron Ireland DAC, Deciphera Pharmaceuticals Switzerland AG, Santhera Pharmaceuticals Schweiz AG
CONTACT
Chief Executive Officer: Constantinos Evripides
Address: 270, Kifissias Av., 152 32 Halandri Greece
- Telephone:+30 210 87 71 500
- Fax:+30 210 68 93 877
- Website: www.genesispharma.com
- Email: [email protected]